YOUR NEW RYBELSUS® TABLETS

(semaglutide tablets)

— WHAT YOU NEED TO KNOW

A new formulation of RYBELSUS® is replacing the previous formulation



The new RYBELSUS® tablets have been improved to help your body absorb the medication more effectively than your previous RYBELSUS® tablets. **This means you can get similar results with a smaller tablet**

What has changed?



Reduced doses



Smaller tablets



Smaller packaging

What has **stayed the same?**



Treatment effects



The way you take it



Possible side effects

Your previous RYBELSUS® tablets

Your new RYBELSUS® tablets





3 mg





1.5 mg





7 mg





4 mg





14 mg







9 mg

The pack shots and tablet images are for illustrative purposes only and do not reflect the actual size of the pack or tablet.

This material has been produced and funded by Novo Nordisk for UK-based adult patients who have already been prescribed RYBFI SUS®.

This information does not replace the package leaflet, which you are advised to read in full. It is not intended as a substitute for clinical advice provided by your healthcare professional.

This material is designed to be viewed digitally. It contains hyperlinks which are viewable online only.

Please contact your healthcare professional if you have any questions about your treatment and for clinical advice.

Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store. Side effects should also be reported to Novo Nordisk Limited (Telephone Novo Nordisk Customer Care Centre 0800 023 2573). Calls may be monitored for training purposes. By reporting side effects, you can help provide more information on the safety of this medicine.



Take your new RYBELSUS® tablets the same way as before



Take your RYBELSUS® tablet on **an empty stomach** after a recommended fasting period of at least 8 hours



Swallow your RYBELSUS® tablet **whole with a sip of water** (up to 120 ml). Do not split, crush or chew the tablet, as it is not known if it affects absorption of RYBELSUS®



After taking your RYBELSUS® tablet, wait at least 30 minutes before eating, drinking or taking other oral medicines. Waiting less than 30 minutes lowers the absorption of RYBELSUS®

Things to remember when taking RYBELSUS®

- RYBELSUS® should always be taken as one tablet per day. You should not take two tablets to get the effect of a higher dose
- If you take more RYBELSUS® than you should, talk to your doctor straight away. You may get side effects such as feeling sick (nausea)
- If you forget to take a dose, skip the missed dose and take your normal dose the next day
- Do not stop using RYBELSUS® without talking to your doctor. If you stop using it, your blood sugar levels may increase
- Keep the tablets in their packaging until you are ready to take one, in order to protect them from light and moisture

If you have any further questions, please ask your doctor, pharmacist or nurse

This material is produced and funded by Novo Nordisk Limited, with registered offices at 3 City Place, Beehive Ring Road, Gatwick, West Sussex, RH6 0PA. RYBELSUS® and Novo Nordisk® are trademarks owned by Novo Nordisk A/S.

This material is the intellectual property of Novo Nordisk and should not be placed on third-party websites. Novo Nordisk has a responsibility for ensuring that all its materials reflect the most current information.

Job no.: UK25RYB00051 Date of preparation: September 2025



